CD4 and myeloid sarcoma: Stüve et al. recently demonstrated that MS patients undergoing natalizumab therapy exhibited strikingly decreased CD4∶CD8 ratios in the CSF (comparable to those of an HIV-1-infected patient cohort) compared to MS patients not receiving natalizumab and they attributed this to decreased migration of CD4+ T cells into the CNS [10], [12].